KR20230054440A - 심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드 - Google Patents

심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드 Download PDF

Info

Publication number
KR20230054440A
KR20230054440A KR1020237009638A KR20237009638A KR20230054440A KR 20230054440 A KR20230054440 A KR 20230054440A KR 1020237009638 A KR1020237009638 A KR 1020237009638A KR 20237009638 A KR20237009638 A KR 20237009638A KR 20230054440 A KR20230054440 A KR 20230054440A
Authority
KR
South Korea
Prior art keywords
peptide
subject
aid
tat
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237009638A
Other languages
English (en)
Korean (ko)
Inventor
리비아 훌
Original Assignee
더 유니버시티 오브 웨스턴 오스트레일리아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902986A external-priority patent/AU2020902986A0/en
Application filed by 더 유니버시티 오브 웨스턴 오스트레일리아 filed Critical 더 유니버시티 오브 웨스턴 오스트레일리아
Publication of KR20230054440A publication Critical patent/KR20230054440A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
KR1020237009638A 2020-08-21 2021-08-20 심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드 Pending KR20230054440A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902986A AU2020902986A0 (en) 2020-08-21 Peptides for Use in the Treatment or Prevention of Myocardial Damage
AU2020902986 2020-08-21
PCT/AU2021/050928 WO2022036411A1 (en) 2020-08-21 2021-08-20 Peptides for use in the treatment or prevention of myocardial damage

Publications (1)

Publication Number Publication Date
KR20230054440A true KR20230054440A (ko) 2023-04-24

Family

ID=80322294

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237009638A Pending KR20230054440A (ko) 2020-08-21 2021-08-20 심근 손상의 치료 또는 예방에 사용하기 위한 펩타이드

Country Status (8)

Country Link
US (1) US20240158447A1 (https=)
EP (1) EP4200314A4 (https=)
JP (1) JP7776492B2 (https=)
KR (1) KR20230054440A (https=)
CN (1) CN116615438A (https=)
AU (1) AU2021327085A1 (https=)
CA (1) CA3189838A1 (https=)
WO (1) WO2022036411A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491523B2 (en) * 2004-05-11 2009-02-17 Hirsch Joel A Voltage-dependent calcium channel beta subunit functional core
EP2173372B1 (en) * 2007-06-18 2014-11-19 Agency for Science, Technology and Research Novel peptides and protein and uses thereof
WO2013113060A1 (en) * 2012-01-31 2013-08-08 The University Of Western Australia Peptide
US11474098B2 (en) * 2017-12-22 2022-10-18 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same

Also Published As

Publication number Publication date
WO2022036411A9 (en) 2025-10-02
AU2021327085A1 (en) 2023-03-02
JP2023537934A (ja) 2023-09-06
EP4200314A4 (en) 2025-01-01
CA3189838A1 (en) 2022-02-24
JP7776492B2 (ja) 2025-11-26
CN116615438A (zh) 2023-08-18
EP4200314A1 (en) 2023-06-28
US20240158447A1 (en) 2024-05-16
WO2022036411A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
BRPI0710223A2 (pt) proteìnas de fusão de receptor de vegf e seu uso
RU2685869C1 (ru) Варианты дизинтегрина и их фармацевтическое применение
KR20200003889A (ko) C-말단 cdnf 및 manf 단편, 이를 포함하는 약학적 조성물 및 그 용도
US8409826B2 (en) TAT-utrophin as a protein therapy for dystrophinopathies
US20260109744A1 (en) Amyloid peptide variants
AU2001259453B2 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
Watkins et al. Plasma membrane cytoskeleton of muscle: a fine structural analysis
AU2001259453A1 (en) Methods for stimulating nervous system regeneration and repair by regulating arginase 1 and polyamine synthesis
JP7776492B2 (ja) 心筋損傷の処置または防止に使用するためのペプチド
MX2007011487A (es) Peptidos de factor de crecimiento mecanico y su uso.
US20140303093A1 (en) Micro-utrophin polypeptides and methods
AU2008265840B2 (en) A method of treating abnormal angiogenesis via the BAI family of proteins and their protein fragments
WO2013113060A1 (en) Peptide
EP4178602A1 (en) Therapeutic use of calcium-activated chloride channel peptide activator
CA2601227A1 (en) Mecano growth factor peptides and their use
CN120676931A (zh) Engrailed蛋白的稳定水性组合物
Belanto A Biochemical and Molecular Analysis of Functional Differences between Dystrophin and Utrophin
MX2011009743A (es) Composiciones y metodos para estimular la diferenciacion neuronal via distrofina dp71?78-79.
WO2009153418A1 (fr) Peptides harp inhibant la croissance tumorale

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902